期刊文献+

利用CRISPR/Cas9n系统敲除人源SNF5基因 被引量:1

Knock-out of Human SNF5 Gene by CRISPR/Cas9n System
下载PDF
导出
摘要 目的:建立敲除人源基因组中SNF5基因的CRISPR/Cas9n系统。方法:设计一对靶向人源SNF5基因第1个外显子的sg RNA,分别克隆至p X461、p X462表达载体后,转入人胚肾293T细胞,通过Western印迹检测细胞株中SNF5基因的敲除效果。结果:测序证明构建的靶向SNF5基因CRISPR/Cas9n重组质粒与设计吻合。Western印迹结果显示,重组质粒p X461-h SNF5sg RNA转染293T细胞后24 h,细胞内SNF5表达水平明显降低;重组质粒p X462-h SNF5sg RNA转染293T细胞后48 h,细胞内SNF5表达水平显著降低。结论:通过CRISPR/Cas9n系统获得了靶向SNF5基因的重组质粒,构建的重组质粒能有效敲除SNF5基因的表达。 Objective:To knock out human SNF5 gene by CRISPR/Cas9 n system.Methods:A pair of sgRNAs targeting exon 1 of human SNF5 gene were designed and subcloned into the pX461 and pX462 vectors,and then transfected into human embryo kidney 293 T cells.The effect of recombination plasmids on the expression of SNF5 gene was identified by western blotting.Results:CRISPR/Cas9 n plasmids targeting SNF5 gene were confirmed by DNA sequencing.Western blotting showed that SNF5 protein decreased obviously when 293 T cells were transfected with recombinant plasmid pX461-hSNF5 sgRNAs for 24 h,and decreased significantly when 293 T cells were transfected with recombinant plasmid pX462-hSNF5 sgRNAs for 48 h.Conclusion:CRISPR/Cas9 n palsmids targeting human SNF5 gene were successfully constructed and could knock out the expression of SNF5 gene effectively.
出处 《生物技术通讯》 CAS 2015年第6期751-754,共4页 Letters in Biotechnology
基金 国家自然科学基金面上项目(81171899) 国家自然科学基金青年科学基金(81100239) 天津市高等学校科技发展基金(093-201301)
关键词 CRISPR/Cas9n系统 SNF5基因 表观遗传 CRISPR/Cas9n system SNF5 gene epigenetic
  • 相关文献

参考文献19

  • 1Chylinski K, Le Rhun A, Charpentier E. The tracrRNA and Cas9 families of type II CRISPRCas immunity systems[J]. RNA Biol, 2013,10(5):726-737.
  • 2Jinek M, Chylinski K, Fonfara I, et al. A programmable dual- RNA-guided DNA endonueIease in adaptive bacterial immunity [J]. Science, 2012,337(6096):816-821.
  • 3Sapranauskas R, Gasiunas G, Fremaux C, et al. The Strepto- coccus thermophilus CRISPR/Cas system provides immunity in Escberichia coli[J]. Nucleic Acids Res, 2011,39(21):9275- 9282.
  • 4Mali P, Esvelt K M, Church G M. Cas9 as a versatile tool for engineering biology[J]. Nat Methods, 2013,10(10):957-963.
  • 5Brenea M, Rossi S, Lorenzetto E, et al. SMARCB1/INI1 genet- ic inactivation is responsible for tumorigenic properties of epi- thelioid sarcoma cell line VAESBJ[J]. Mol Cancer Ther, 2013, 12(6):1060-1072.
  • 6Carter J M, O'Hara C, Dundas G, et al. Epithelioid malig-nant peripheral nerve sheath tumor arising in a schwannoma, in a patient with "neuroblastoma-like" schwannomatosis and a novel germline SMARCB1 mutation[J]. Am J Surg Pathol, 2012,36(1):154-160.
  • 7Hulsebos T J, Plomp A S, Woherman R A, et al. Germline mutation of INI1/SMARCB1 in familial schwannomatosis[J]. Am J Hum Geuet, 2007,80(4):805-810.
  • 8Kohashi K, Oda Y, Yamamoto H, et al. SMARCB1/INI1 pro- tein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special ref- erence to SMARCB1/INI1 negative variant extraskeletal myx- old chondrosarcoma[J]. Am J Surg Pathol, 2008,32(8):1168- 1174.
  • 9Mimori K, Inoue H, Shiraishi T, et al. A single-nucleotide polymorphism of SMARCB1 in human breast cancers[J]. Ge- nomics, 2002,80(3):254-258.
  • 10Rizzo D, Freneaux P, Brisse H, et al. SMARCB1 deficiency in tumors from the peripheral nervous system: a link between schwannomas and rhabdoid tumors[J]? Am J Surg Pathol, 2012,36(7):964-972.

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部